3-[3-[[(9H-fluoren-9-yl)methyloxycarbonyl]amino]propanamido]propionic acid | 855316-46-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 3-[3-[[(9H-fluoren-9-yl)methyloxycarbonyl]amino]propanamido]propionic acid
• 英文别名: 3-[(3-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}propanoyl)amino]propanoic acid；3-[3-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)propanamido]propanoic acid；3-[3-(9H-fluoren-9-ylmethoxycarbonylamino)propanoylamino]propanoic acid
• CAS: 855316-46-0
• 化学式: C₂₁H₂₂N₂O₅
• 分子量: 382.416
• InChiKey: SIGCYSMTUQWCQG-UHFFFAOYSA-N

物化性质

• 沸点：
  700.8±50.0 °C(Predicted)
• 密度：
  1.284±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-[3-[[(9H-fluoren-9-yl)methyloxycarbonyl]amino]propanamido]propionic acid 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 72.0h， 生成 [4-[[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]amino]phenyl]methyl 3-[3-[3-(9H-fluoren-9-ylmethoxycarbonylamino)propanoylamino]propanoylamino]propanoate
  参考文献：
  名称：

  Solution phase synthesis of β-peptides using micro reactors

  摘要：

  The synthesis of beta-peptides has been successfully performed using a borosilicate glass micro reactor, in which a network of channels has been produced using a photolithographic and wet etching method. The reagents were mobilised by electroosmotic flow (EOF). The micro reactor was initially evaluated using a carbodiimide coupling reaction to form a dipeptide. The methodology has been extended such that the peptides may also be produced via the pentafluorophenyl ester derivatives of amino acids. It was found that performing the pentafluorophenyl ester reactions in the micro reactor resulted in an increase in the reaction efficiency over the traditional batch method. We postulate that the enhancement in rate of reaction is an electrochemical phenomenon, due to the reaction being performed in an electric field, which is unique to micro reactor systems. It has also been demonstrated that selective deprotection of the resultant dipeptides can be achieved. This approach has been used in the synthesis of a tripeptide. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(02)00513-6
• 作为产物：
  描述：

  t-butyl 3-[3-[[(9H-fluoren-9-yl)methyloxycarbonyl]amino]propanamido]propionate 在 三氟乙酸 作用下， 以 氯仿 为溶剂， 反应 3.0h， 以0.65 g的产率得到3-[3-[[(9H-fluoren-9-yl)methyloxycarbonyl]amino]propanamido]propionic acid
  参考文献：
  名称：

  Synthesis and structure of a bis-glycosylated hexa-β-peptide

  摘要：

  The bis-glycosylated hexapeptide beta-Ala-beta-Ala-(beta-D-Glc)-L-Asp-beta-Ala-beta-Ala-(beta-D-Gal)-L-Asp (14) is prepared by fragment condensation of Fmoc-beta-Ala-beta-Ala-(beta-D-GlcAc(4))-L-Asp-OH (11) and H2N-beta-Ala-beta-Ala-(beta-D-GalAc(4))-L-Asp-(OBu)-Bu-t (12) under optimized conditions with the HBTU/HOBt reagent followed by deprotection of the intermediate fully protected hexapeptide. Hexapeptide 14 is shown to adopt a random coil structure in solution.

  DOI：

  10.3998/ark.5550190.0014.227

文献信息

• GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS
  申请人：BRADSHAW Curt W.

  公开号：US20090098130A1

  公开（公告）日：2009-04-16

  The present invention provides GA targeting compounds which comprise GA targeting agent-linker conjugates linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.

  本发明提供了包括连接到抗体结合位点的GA靶向剂-连接剂共轭物的GA靶向化合物。提供了化合物的各种用途，包括预防或治疗糖尿病或与糖尿病相关的疾病的方法。
• ANTI-ANGIOGENIC COMPOUNDS
  申请人：Bradshaw Curt

  公开号：US20080166364A1

  公开（公告）日：2008-07-10

  The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.

  本发明提供了包括与抗体的结合位点连接的AA靶向剂-连接剂共轭物的AA靶向化合物。提供了化合物的各种用途，包括治疗与异常血管生成相关的疾病的方法。
• DISRUPTORS OF EARLY/RECYCLING ENDOSOMES
  申请人：Peterson Blake R.

  公开号：US20100041773A1

  公开（公告）日：2010-02-18

  A delivery system for introducing a cargo molecule into cytosol of a living cell can include: a first membrane binding element linked to an endosomal compartment disrupting element through a first linker having one or more anionic moieties; and a second membrane binding element linked to an exogenous cargo molecule through a second linker having one or more anionic moieties, the second linker having a region that is selectively cleavable, wherein the first and second membrane binding elements both induce endocytosis into an early/recycling endosome and the endosomal compartment disrupting element destabilizes the early/recycling endosome such that the exogenous cargo molecule is released from the second membrane binding element and into the cytosol of the living cell.

  一种将货物分子引入生物细胞细胞质的传递系统可以包括：第一膜结合元素通过具有一个或多个阴离子基团的第一连接物与内体区域破坏元素相连；第二膜结合元素通过具有一个或多个阴离子基团的第二连接物与外源货物分子相连，第二连接物具有可选择裂解的区域，其中第一和第二膜结合元素均诱导内吞作用进入早期/循环内体，内体区域破坏元素破坏早期/循环内体，使外源货物分子从第二膜结合元素中释放并进入生物细胞细胞质。
• Anti-Angiogenic Compounds
  申请人：Bradshaw Curt W.

  公开号：US20080152660A1

  公开（公告）日：2008-06-26

  The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.

  本发明提供了AA靶向化合物，其中包括与抗体结合位点连接的AA靶向剂-连接剂共轭物。提供了化合物的各种用途，包括治疗与异常血管生成有关的疾病的方法。
• COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS
  申请人：Covx Technologies Ireland Ltd.

  公开号：US20150057431A1

  公开（公告）日：2015-02-26

  The present invention provides methods of treating (including preventing) a disease or condition associated with abnormal angiogenesis in a subject include administering a therapeutically effective amount of an AA targeting compound of the invention to the subject. The AA targeting compounds comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody.

  本发明提供了治疗（包括预防）与受试者中异常血管生成相关的疾病或病状的方法，包括向受试者施用本发明的AA靶向化合物的治疗有效剂量。AA靶向化合物包括与抗体的结合位点连接的AA靶向剂-连接剂共轭物。